Under the Paperwork Reduction Act of 1995, no persons are required to re

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number Filing Date First Named Inventor Andre Art Unit		10774319		
		2004-02-06		
		w R. Barron		
		1773		
Examiner Name	Hoa T.	Le		
Attorney Docket Number		1789-12001 MDW		

					U.S.	PATENTS			Remove	
Examiner Initial*	raminer Cite No Patent Number Kind Code1 Issue Date Name of Patentee or App			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear						
	1									
If you wis	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add	
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee or Applicant of cited Document		Releva	Columns,Lines where int Passages or Relev s Appear	
	1									
If you wisl	h to a	dd additional U.S. Publ		,				d button		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date Name of Patentee or Applicant of cited Document		e or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	+
	1									
If you wisl	h to a	dd additional Foreign P	atent Do	cument	citation	information pl	ease click the Add	button	Add	
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove	
Examiner Cite Initiats* Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						Τs				

			_				
	1	DeFriend, Kimberly A., et al., A Single approach to Hierarchical Ceramic Ultrafiltration Membranes, Journal of Membrane Science, 2003, (pp. 29-38)					
2 DeFriend, Kimberry A, et al; Surface Repair of Porous and Damagerd Alumina Bodies Using Carboxylate-Alumoxan Nanoparticles, Journal of Materials Science 37, 2002, (pp. 2969-2916.							
Callender, Rhonde L., et al.: Aqueous Synthesis of Water-Soluble Aumoxanes: Environmentally Benign Precursors Alumina and Aluminum-Based Ceramics 1997 American Chemical Society. (pp. 2418-2433)							
If you wish to add additional non-patent literature document citation information please click the Add button Add							
EXAMINER SIGNATURE							

Examiner Signature Date Considered FEXAMINER: initial if reference considered, whether or not citation is in conformance with MIPEP 609. Draw line through a citation in for nonformance and not considered, include copy of this form with next communication to applicant.

See Kint Codes of USPTO Patent Documents at swer USPTO_GOLY or MPEP 901.04. Esters office that issued the document, by the low-letter gold (WIPO Standard ST3.). "For Laplanese patent counters, the includation of the year of the register or impressed the sent number the patent document." A fund of document by the appropriate symbols as indicated on the document under WIPO Standard ST1.6 if possible. "Applicant is to place a check mark here if English language streatistics in statistact."

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10774319			
Filing Date		2004-02-06			
First Named Inventor	Andre	ew R. Barron			
Art Unit		1773			
Examiner Name	Hoa T. Le				
Attorney Docket Number		1789-12001 MDW			

CERTIFICATION STATEMENT

Please see 37	CFR 1.97 and	1.98 to make the appropriate selection(s):
---------------	--------------	--

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sec 37 CFR 137(eVI).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 175(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 179(c) and the statement. See 37 CFR 179(c) and the statement. See 37 CFR 179(c) and the statement is set to the statement of the statement of

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☐ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Marcella D. Watkins	Date (YYYY-MM-DD)	2006-07-24
Name/Print	Marcella D. Watkins	Registration Number	36962

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicide is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually the principal purpose and for examines your submission, which may visually intermediate or of extended now about the principal purpose.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuint to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.